JNJ Stock Price Today (October 2026) — Johnson & Johnson Analysis & Key Metrics 2026-10-21
Johnson & Johnson (JNJ) is trading at $259.36, up 2.19% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $279.27 (7.7% upside).
- Volatility is moderate (27.22% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.60% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
JNJ Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Johnson & Johnson - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $653.31B
P/E Ratio
Forward P/E: 21.60
Revenue Growth
Year over Year
Analyst Target
+7.7% upside potential
Key Investor Questions About JNJ
What investors need to know before buying
Based on current market data, JNJ presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 47.78)
- Fundamentals say: Looking solid (debt and growth supportive)
JNJ's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for JNJ investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $49.04B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, JNJ stock traded between $184.66 and $281.07 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 27.22% annualized volatility and β=-0.10, the stock exhibits low sensitivity to market moves—making JNJ suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Dow outperforms as Wall Street rises, healthcare stocks lead gains
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?
Rapport’s novel oral drug posts Phase II bipolar win
Johnson & Johnson (JNJ) Debuts New Coronary Catheter In The U.S.
Latest TickZen Insights
All insights →No TickZen article on JNJ yet. Our newest analysis:
Explore More Analysis for JNJ
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
No upcoming report date yet
Frequently Asked Questions
Common investor questions about Johnson & Johnson
Johnson & Johnson (JNJ) is currently trading at $259.36. The RSI (14-day) is at 47.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $279.27 implies 7.7% upside from current levels. Volatility is moderate at 27.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Johnson & Johnson (JNJ): The trailing P/E ratio is 31.11, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 21.60, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 4.66, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 7.55. Price-to-Sales is 6.55. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering JNJ, the consensus price target is $279.27. This represents a 7.7% upside from the current price of $259.36. The range spans from a low target of $190.00 to a high target of $320.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Johnson & Johnson (JNJ) pays a dividend with a current yield of approximately 2.16%. The annualized dividend rate is $1.30 per share. The payout ratio is 60.7%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Nov 24, 2026.
Key risks for Johnson & Johnson (JNJ) investors include: 1. Moderate volatility (27.2% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Johnson & Johnson's (JNJ) current debt and financial health profile: Total debt stands at $49.04B. The debt-to-equity ratio is 0.58x, which is moderate and generally manageable for most companies. The current ratio is 1.09, indicating adequate short-term liquidity. The quick ratio is 0.73. The company holds $20.76B in cash and equivalents. Free cash flow is positive at $16.89B, providing a cushion for debt servicing and shareholder returns.